{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HPV16+Associated+Cervical+Cancer",
    "query": {
      "condition": "HPV16 Associated Cervical Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HPV16+Associated+Cervical+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:39:20.723Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02405221",
      "title": "Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HPV16 Associated Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "TA-CIN (arm)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TA-CIN (thigh)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2019-04-04",
      "completion_date": "2025-01-31",
      "has_results": true,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-05-22T05:39:20.723Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02405221"
    },
    {
      "nct_id": "NCT05973487",
      "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Cervical Cancer",
        "Non-small Cell Carcinoma",
        "Melanoma",
        "Ovarian Cancer",
        "Anogenital Cancers",
        "HPV - Anogenital Human Papilloma Virus Infection",
        "HPV-Related Cervical Carcinoma",
        "HPV-Related Carcinoma",
        "HPV-Related Squamous Cell Carcinoma",
        "HPV-Related Malignancy",
        "HPV-Related Adenocarcinoma",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "HPV-Related Adenosquamous Carcinoma",
        "HPV-Associated Vaginal Adenocarcinoma",
        "HPV-Related Endocervical Adenocarcinoma",
        "HPV-Related Anal Squamous Cell Carcinoma",
        "HPV-Related Verrucous Carcinoma",
        "HPV-Related Penile Squamous Cell Carcinoma",
        "HPV-Related Vulvar Squamous Cell Carcinoma",
        "HPV Positive Rectal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "TSC-204-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-204-C0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0101 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-201-B0702 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TScan Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 840,
      "start_date": "2024-05-06",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-05-22T05:39:20.723Z",
      "location_count": 21,
      "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05973487"
    },
    {
      "nct_id": "NCT02280811",
      "title": "T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Vaginal Cancer",
        "Cervical Cancer",
        "Anal Cancer",
        "Penile Cancer",
        "Oropharyngeal Cancer"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "E6 TCR",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-10-14",
      "completion_date": "2016-06-28",
      "has_results": true,
      "last_update_posted_date": "2017-09-06",
      "last_synced_at": "2026-05-22T05:39:20.723Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02280811"
    },
    {
      "nct_id": "NCT04672980",
      "title": "RTX-321 Monotherapy in Patients With HPV 16+ Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Head and Neck Cancer",
        "Anal Cancer"
      ],
      "interventions": [
        {
          "name": "RTX-321",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rubius Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2021-04-08",
      "completion_date": "2022-11-30",
      "has_results": false,
      "last_update_posted_date": "2022-12-08",
      "last_synced_at": "2026-05-22T05:39:20.723Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04672980"
    },
    {
      "nct_id": "NCT01493154",
      "title": "Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2,
      "start_date": "2012-04",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2018-11-23",
      "last_synced_at": "2026-05-22T05:39:20.723Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01493154"
    },
    {
      "nct_id": "NCT07172256",
      "title": "CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "New Diagnosis Tumor",
        "Locally Advanced"
      ],
      "interventions": [
        {
          "name": "CUE-101",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-05-07",
      "completion_date": "2031-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T05:39:20.723Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07172256"
    },
    {
      "nct_id": "NCT07209189",
      "title": "Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma",
        "Oral Cavity Cancer",
        "Oropharyngeal Cancer",
        "Laryngeal Cancer",
        "Sinonasal Squamous Cell Carcinoma",
        "HPV (Human Papillomavirus)-Associated Carcinoma",
        "Skull Base Tumors",
        "HPV 16 Positive Oropharyngeal Tumors (OPC)"
      ],
      "interventions": [
        {
          "name": "Toripalimab + Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Toripalimab",
          "type": "DRUG"
        },
        {
          "name": "Chemoradiotherapy or radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2026-02-18",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-05-22T05:39:20.723Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07209189"
    },
    {
      "nct_id": "NCT07281599",
      "title": "Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HPV Infection",
        "HPV 16 Infection",
        "High Risk HPV",
        "Cervical Cancer Screening",
        "Cervical Cancer Cin Grade",
        "Cervical Cancer (Early Detection)",
        "HPV",
        "HPV (Human Papillomavirus)-Associated",
        "HPV DNA",
        "HPV Infections",
        "Screening Test"
      ],
      "interventions": [
        {
          "name": "Q-Pad hrHPV Test System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Qurasense",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "25 Years and older · Female only"
      },
      "enrollment_count": 450,
      "start_date": "2025-12-01",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-05-22T05:39:20.723Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Minneapolis, Minnesota • Akron, Ohio + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07281599"
    },
    {
      "nct_id": "NCT05232851",
      "title": "A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Human Papillomavirus-Related Carcinoma",
        "Locally Advanced Oropharyngeal Carcinoma",
        "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "FDG-Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-06-16",
      "completion_date": "2026-09-10",
      "has_results": true,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-05-22T05:39:20.723Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05232851"
    },
    {
      "nct_id": "NCT03439085",
      "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Papillomavirus-16 Positive",
        "Human Papillomavirus-18 Positive",
        "Metastatic Malignant Neoplasm",
        "Recurrent Anal Canal Carcinoma",
        "Recurrent Cervical Carcinoma",
        "Recurrent Malignant Neoplasm",
        "Recurrent Penile Carcinoma",
        "Recurrent Vaginal Carcinoma",
        "Recurrent Vulvar Carcinoma",
        "Refractory Malignant Neoplasm",
        "Stage IV Anal Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Penile Cancer AJCC v8",
        "Stage IV Vaginal Cancer AJCC v8",
        "Stage IV Vulvar Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Vaginal Cancer AJCC v8",
        "Stage IVA Vulvar Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Vaginal Cancer AJCC v8",
        "Stage IVB Vulvar Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2018-11-14",
      "completion_date": "2022-09-20",
      "has_results": true,
      "last_update_posted_date": "2024-07-09",
      "last_synced_at": "2026-05-22T05:39:20.723Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03439085"
    }
  ]
}